What is "tigatuzumab"

n. A monoclonal antibody for the treatment of cancer.

Tigatuzumab (CS-1008) is a monoclonal antibody for the treatment of cancer. , a clinical trial for the treatment of pancreatic cancer has been completed, Phase II trials for colorectal cancer and non-small cell lung cancer are running, and a study for ovarian cancer has been approved.

The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein overexpressed in many kinds of tumour.

A recent study reports on the preclinical validation of 111In-labeled anti-DR5 humanised antibody CS-1008 as a diagnostic tool to study the DR5 occupancy in cancer patients, and establish dose ranges for receptor saturation kinetics in vivo.